OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
Zacks News
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
by Zacks Equity Research
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
Best Momentum Stocks to Buy for July 19th
by Zacks Equity Research
NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.
New Strong Buy Stocks for July 19th
by Zacks Equity Research
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
RMTI, ZUO and OPK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2023.
Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment
by Zacks Equity Research
The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
by Zacks Equity Research
The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.
Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
by Zacks Equity Research
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business, and informatics franchise.
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.
Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.
3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Here's Why You Should Hold OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -10% and 4.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Beats Q2 Earnings Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?